Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

About this update from Cerus Corporation

[{"type":"text","content":"\nFull-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively, from Prior Year Periods\n\nFourth straight quarter of positive operating cash flows\n\nReiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024.\n\nRecent highlights include:\n\n\nTotal revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %):\n\n\n\n\n\nThree Months Ended\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTwelve Months Ended\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\nDecember 31,\n\n\n\n \n\n\n\nChange\n\n\n\n \n\n\n\nDecember 31,\n\n\n\n \n\n\n\nChange\n\n\n\n\n\n \n\n\n\nUnaudited\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nUnaudited\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n \n\n\n\n2023\n\n\n\n \n\n\n\n$\n\n\n\n \n\n\n\n%\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n2023\n\n\n\n \n\n\n\n$\n\n\n\n \n\n\n\n%\n\n\n\n\n\nProduct Revenue\n\n\n\n$\n\n\n\n50,809\n\n\n\n \n\n\n\n$\n\n\n\n46,768\n\n\n\n \n\n\n\n$\n\n\n\n4,041\n\n\n\n \n\n\n\n \n\n\n\n9\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n180,270\n\n\n\n \n\n\n\n$\n\n\n\n156,367\n\n\n\n \n\n\n\n$\n\n\n\n23,903\n\n\n\n \n\n\n\n \n\n\n\n15\n\n\n\n%\n\n\n\n\n\nGovernment Contract Revenue\n\n\n\n \n\n\n\n5,942\n\n\n\n \n\n\n\n \n\n\n\n6,574\n\n\n\n \n\n\n\n \n\n\n\n(632\n\n\n\n)\n\n\n\n \n\n\n\n-10\n\n\n\n%\n\n\n\n \n\n\n\n \n\n\n\n21,051\n\n\n\n \n\n\n\n \n\n\n\n30,430\n\n\n\n \n\n\n\n \n\n\n\n(9,379\n\n\n\n)\n\n\n\n \n\n\n\n-31\n\n\n\n%\n\n\n\n\n\nTotal Revenue\n\n\n\n$\n\n\n\n56,751\n\n\n\n \n\n\n\n$\n\n\n\n53,342\n\n\n\n \n\n\n\n$\n\n\n\n3,409\n\n\n\n \n\n\n\n \n\n\n\n6\n\n\n\n%\n\n\n\n \n\n\n\n$\n\n\n\n201,321\n\n\n\n \n\n\n\n$\n\n\n\n186,797\n\n\n\n \n\n\n\n$\n\n\n\n14,524\n\n\n\n \n\n\n\n \n\n\n\n8\n\n\n\n%\n\n\n\n\n\nThe Company is reiterating its full-year 2025 annual product revenue guidance range of $194 million to $200 million, which includes $12 million to $15 million for INTERCEPT Fibrinogen Complex (IFC).\n\n\nContinued financial execution for full year and Q4 2024:\n\n\nOver 40% improvement in 2024 GAAP net loss attributable to Cerus Corporation to $20.9 million from $37.5 million for ...

More updates from Cerus Corporation